Clinical Trial Update: MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004) [Phase 1]

View source ↗

Summary

Merck completed a single-dose Phase 1 trial (MK-8527-004) in HIV-1 infected participants; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MK-8527

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Human Immunodeficiency Virus | Phase 1 | Status: COMPLETED | Results posted: 2025-03-26